慢性丙型肝炎抗病毒治疗的历史和未来  

History and future of antiviral therapy of chronic hepatitis C

作　　者：宁钢[1] 林潮双[1] 

机构地区：[1]中山大学附属第三医院感染病科广东省肝脏病疾病研究重点实验室,广东省广州市510630

出　　处：《世界华人消化杂志》2016年第14期2117-2130,共14页World Chinese Journal of Digestology

基　　金：广州市科技计划基金资助项目;No.1561000155;中山大学临床医学研究5010计划基金资助项目;No.2010011;高等学校学科创新引智计划(111项目)基金资助项目;No.B12003~~

摘　　要：丙型肝炎病毒(hepatitis C virus,HCV)感染慢性化率高,抗病毒治疗是阻止慢性丙型肝炎(chronic hepatitis C,CHC)进展为终末期肝病的重要手段.至今,CHC抗病毒治疗先后经历了干扰素单药治疗、普通干扰素与利巴韦林(ribavirin,RBV)联合治疗以及聚乙二醇干扰素与RBV联合治疗的时代,目前正进入直接抗病毒药物(direct-acting antiviral agents,DAAs)治疗的新时代.与艾滋病的鸡尾酒疗法相似,未来CHC抗病毒治疗将以联合治疗为主,这些药物耐受性好,耐药率低,治愈率高,而且可以显著缩短疗程.本文将就CHC抗病毒治疗的历史和未来进行简要综述.Hepatitis C virus（HCV） infection often leads to chronic diseases,and antiviral therapy is an important way to prevent chronic hepatitis C from progressing to end-stage liver disease.Up to now,hepatitis C antiviral therapy has successively experienced eras of interferon monotherapy,interferon and ribavirin combination therapy,and combination therapy of pegylated-interferon（PEG-IFN） and ribavirin.Now we are entering into a new era of direct-acting antiviral agents（DAAs）.Just like acquired immune deficiency syndrome（AIDS） cocktails,combination therapy consists of two or more antiviral agents.DAAs will be the primary antiviral therapy for hepatitis C in the future for their better tolerance,lower drug resistance,higher sustained virological response and shorter treatment course.In this article,we review the history and future of antiviral therapy of HCV infection.

关 键 词：丙型肝炎病毒 抗病毒治疗 干扰素 直接抗病毒药物 

分 类 号：R512.63[医药卫生—内科学]